Study of Obeldesivir as Postexposure Prophylaxis for Filovirus Diseases Virus Disease

Stopped The study was withdrawn after the Marburg outbreak in Rwanda was declared over, prior to enrollment of any participants.

Conditions

• Filovirus Disease
• Postexposure Prophylaxis for Filovirus Disease

Interventions

• DRUG: obeldesivir

Sponsor

Gilead Sciences